UNSPSC 51123115: Pincainide

This classification denotes an antiarrhythmic agent and anesthetic agent with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 66803GMO3G, chemically known as 2,3,4,5,6,7-hexahydro-1h-azepine-1-aceto-2,6-xylidide but more generally known as pincainide, which bears US NIH Compound Identifier 71267. European Medicines Agency schedules Pincainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09853MIG.

UNSPSC 51123115 Pincainide (Commodity) encompasses antiarrhythmic medications supplied to emergency medical services, healthcare facilities, and state pharmacy benefit programs. State and local governments use this code to procure specific pharmaceutical products — in recent activity, advanced life support medications including antiarrhythmics and related injectables for first-responder use. Issuing bodies include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue department and the Texas Health and Human Services Commission are recent buyers, with the latter exploring direct-to-manufacturer pharmacy procurement models alongside traditional wholesale distribution channels. Suppliers must hold current Good Manufacturing Practices certification, comply with Drug Supply Chain Security Act requirements, maintain comprehensive liability insurance, and provide Safety Data Sheets compliant with OSHA Hazard Communication Standards.

Geographic activity centers on Florida and Texas, with broader multistate participation through cooperative purchasing vehicles such as MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), which extends across participating states including Oregon. Recent representative opportunities include the City of Tampa's sealed bid (26P00188) for Advanced Life Support Medications with a March 26, 2026 response deadline and $40,000 estimated contract value, specifying delivery within ten calendar days and nine-month minimum expiration dates; the Texas HHS Commission's Request for Information (HHS0017013) posted April 3, 2026 to assess vendor capacity for direct-to-manufacturer pharmacy initiatives; and MMCAP's Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals with a March 26, 2026 deadline, requiring suppliers to work through three authorized wholesalers and accept a 3 percent administrative fee. The City of Tampa's solicitation includes a Small Local Business Enterprise sheltered market with 5 percent bid discount available, and all submissions must demonstrate WCAG 2.2 Level AA accessibility compliance.